Compound News and Research

RSS

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today it has in-licensed BL-1110, a novel compound for the treatment of neuropathic pain.

23 Jun 2014

New driver of atherosclerosis may prove to be promising therapeutic target

A new driver of atherosclerosis has been identified by researchers at UT Southwestern Medical Center. This molecule, known as 27HC (27-hydroxycholesterol), has been found to exacerbate the development of the condition, and may prove to be a promising therapeutic target.

20 Jun 2014

Janssen signs license agreement with Vertex to develop, commercialize VX-787 for influenza A treatment

Janssen Pharmaceuticals, Inc.announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787, a novel medicine in Phase II development for the treatment of influenza A.

18 Jun 2014

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

Australian oncology drug development company Novogen Limited and CanTx Inc., its joint venture with Yale University, today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity.

18 Jun 2014

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

Symplmed announced today that the U.S. Food and Drug Administration has accepted for review its New Drug Application (NDA) for investigational drug Prestalia, the first single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate for the treatment of hypertension in the U.S. Symplmed filed the application under section 505(b)(2) consistent with FDA's guidance.

18 Jun 2014

Compound developed as cholesterol-fighting molecule can kill cancerous cells

Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of breast cancer, but also can kill the cancerous cells.

18 Jun 2014

New hope for people suffering from depression

There is new hope for people suffering from depression. Researchers have identified a compound, hydroxynorketamine (HNK), that may treat symptoms of depression just as effectively and rapidly as ketamine, without the unwanted side effects associated with the psychoactive drug, according to a study in the July issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists- (ASA-).

17 Jun 2014

Hill-Rom announces signing of definitive agreement to purchase TRUMPF Medical

Hill-Rom Holdings, Inc. today announced the signing of a definitive agreement to purchase TRUMPF Medical, the medical unit of the privately held TRUMPF Group, for approximately $250 million in cash.

16 Jun 2014

Researchers show how to monitor glucose in diabetes using saliva instead of blood

Treating Diabetes - a major scourge of humanity bothering millions of people - requires a constant monitoring of the human blood for glucose concentrations.

16 Jun 2014

Scientists are now one step closer to pill against obesity

Obesity and diabetes are among the fastest growing health problems in the world, and the hunt is in for a pill that can fight the problem.

13 Jun 2014

NSF awards nearly $200,000 to make environmentally friendly field analyzer

The National Science Foundation has awarded nearly $200,000 to two University of Texas at Arlington researchers teaming with a private company to make an affordable, environmentally friendly field analyzer for arsenic levels in water.

13 Jun 2014

New research collaboration aims to develop better therapies for autoimmune diseases

Seattle Children's Research Institute and biotechnology company Kineta, Inc. today launched the Alliance for Children's Therapeutics (ACT), a first-of-its-kind pediatric research and funding collaboration designed to speed development of new medications for children and teens with lupus nephritis and other autoimmune diseases like multiple sclerosis, Type 1 diabetes and rheumatoid arthritis.

11 Jun 2014

AB SCIEX launches MasterView Food Testing Workflow for QTRAP mass spectrometry systems

AB SCIEX, a global leader in analytical technologies, today announced the launch of the MasterView™ Food Testing Workflow for QTRAP® mass spectrometry systems at the 5th Annual FERA/JIFSAN Symposium on Emerging Issues in Food, in York, UK.

10 Jun 2014

$arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM$

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) in which both parties will contribute to the funding of a Phase 2 clinical study of the Company's lead candidate, ARGX-110, in patients with refractory Waldenström's macroglobulinemia (WM).

10 Jun 2014

Researchers reveal mysterious behavior of individual cells using radioluminescence microscopy

With a new molecular imaging system powerful enough to peer down to 20-micrometer resolution, researchers can now use radioluminescence to examine the characteristics of single, unconnected cells. The result is a fascinating picture of diversity among cells previously assumed to behave the same, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.

10 Jun 2014

Scientists present new method of nickel-carbon heterofullerenes synthesis

Scientists from several British, Spanish and Russian research centers (MIPT, Institute for Spectroscopy RAS, Kurchatov Institute and Kintech Lab Ltd) have come up with a method of synthesizing a new type of nickel-carbon compound.

9 Jun 2014

Discovery of IDE may lead to new treatment approaches for diabetes

The discovery of an inhibitor of the Insulin Degrading Enzyme (IDE), a protein responsible for the susceptibility of diabetes because it destroys insulin in the body, may lead to new treatment approaches for diabetes.

5 Jun 2014

AFFiRiS releases positive study results of AD04 therapeutic drug in Alzheimer patients

AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients.

4 Jun 2014

New technology can non-invasively image human lymphatic system

The human lymphatic system is an important but poorly understood circulatory system consisting of tiny vessels spread throughout the body.

4 Jun 2014

Thrasos presents positive results of THR-184 compound for treatment of acute kidney injury

Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, today presented preclinical results showing that its lead development compound THR-184 can effectively protect against loss of kidney function following acute ischemic injury in rat.

4 Jun 2014

Compound News and Research

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

New driver of atherosclerosis may prove to be promising therapeutic target

Janssen signs license agreement with Vertex to develop, commercialize VX-787 for influenza A treatment

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

Compound developed as cholesterol-fighting molecule can kill cancerous cells

New hope for people suffering from depression

Hill-Rom announces signing of definitive agreement to purchase TRUMPF Medical

Researchers show how to monitor glucose in diabetes using saliva instead of blood

Scientists are now one step closer to pill against obesity

NSF awards nearly $200,000 to make environmentally friendly field analyzer

New research collaboration aims to develop better therapies for autoimmune diseases

AB SCIEX launches MasterView Food Testing Workflow for QTRAP mass spectrometry systems

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

Researchers reveal mysterious behavior of individual cells using radioluminescence microscopy

Scientists present new method of nickel-carbon heterofullerenes synthesis

Discovery of IDE may lead to new treatment approaches for diabetes

AFFiRiS releases positive study results of AD04 therapeutic drug in Alzheimer patients

New technology can non-invasively image human lymphatic system

Thrasos presents positive results of THR-184 compound for treatment of acute kidney injury

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News